Expert consensus on the response to mycoplasma pneumoniae infection outbreaks

ZHU Qian; GONG Lei; HOU Sai; XIAO Yongkang; YANG Kun; ZHAO Kefu; YANG Xiaoxue; YAN Yulu; QIN Wei; WANG Yao; GENG Haoxiang; LIU Yaqian; SUN Yong; DENG Shu; WANG Fei; YE Qin; FAN Yinguang; HUANG Yue'e; YE Jun; CHEN Yeji; LENG Ying; CHEN Jian; SUN Liang; TANG Haiyan; TAN Xiaowei; MA Wanwan; ZHU Biao; AN Zhou; WANG Peng; DENG Guoqiang; BAO Min; LYU Yong; SU Hong; LI Jie; WANG Jinsheng; ZHANG Zhihua; ZHAO Yufeng; XU Yanlong; WU Jiabing

doi:10.16462/j.cnki.zhjbkz.2025.07.014

Volume 29 Issue 7

Jul. 2025

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2025 > 29(7): 844-849

ZHU Qian, GONG Lei, HOU Sai, XIAO Yongkang, YANG Kun, ZHAO Kefu, YANG Xiaoxue, YAN Yulu, QIN Wei, WANG Yao, GENG Haoxiang, LIU Yaqian, SUN Yong, DENG Shu, WANG Fei, YE Qin, FAN Yinguang, HUANG Yue'e, YE Jun, CHEN Yeji, LENG Ying, CHEN Jian, SUN Liang, TANG Haiyan, TAN Xiaowei, MA Wanwan, ZHU Biao, AN Zhou, WANG Peng, DENG Guoqiang, BAO Min, LYU Yong, SU Hong, LI Jie, WANG Jinsheng, ZHANG Zhihua, ZHAO Yufeng, XU Yanlong, WU Jiabing. Expert consensus on the response to mycoplasma pneumoniae infection outbreaks[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(7): 844-849. doi: 10.16462/j.cnki.zhjbkz.2025.07.014

Citation:

ZHU Qian, GONG Lei, HOU Sai, XIAO Yongkang, YANG Kun, ZHAO Kefu, YANG Xiaoxue, YAN Yulu, QIN Wei, WANG Yao, GENG Haoxiang, LIU Yaqian, SUN Yong, DENG Shu, WANG Fei, YE Qin, FAN Yinguang, HUANG Yue'e, YE Jun, CHEN Yeji, LENG Ying, CHEN Jian, SUN Liang, TANG Haiyan, TAN Xiaowei, MA Wanwan, ZHU Biao, AN Zhou, WANG Peng, DENG Guoqiang, BAO Min, LYU Yong, SU Hong, LI Jie, WANG Jinsheng, ZHANG Zhihua, ZHAO Yufeng, XU Yanlong, WU Jiabing. Expert consensus on the response to mycoplasma pneumoniae infection outbreaks[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(7): 844-849. doi: 10.16462/j.cnki.zhjbkz.2025.07.014

Citation:

ZHU Qian, GONG Lei, HOU Sai, XIAO Yongkang, YANG Kun, ZHAO Kefu, YANG Xiaoxue, YAN Yulu, QIN Wei, WANG Yao, GENG Haoxiang, LIU Yaqian, SUN Yong, DENG Shu, WANG Fei, YE Qin, FAN Yinguang, HUANG Yue'e, YE Jun, CHEN Yeji, LENG Ying, CHEN Jian, SUN Liang, TANG Haiyan, TAN Xiaowei, MA Wanwan, ZHU Biao, AN Zhou, WANG Peng, DENG Guoqiang, BAO Min, LYU Yong, SU Hong, LI Jie, WANG Jinsheng, ZHANG Zhihua, ZHAO Yufeng, XU Yanlong, WU Jiabing. Expert consensus on the response to mycoplasma pneumoniae infection outbreaks[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(7): 844-849. doi: 10.16462/j.cnki.zhjbkz.2025.07.014

PDF( 772 KB)

Expert consensus on the response to mycoplasma pneumoniae infection outbreaks

doi: 10.16462/j.cnki.zhjbkz.2025.07.014

ZHU Qian¹,
GONG Lei¹,
HOU Sai¹,
XIAO Yongkang¹,
YANG Kun²,
ZHAO Kefu³,
YANG Xiaoxue¹,
YAN Yulu¹,
QIN Wei⁴,
WANG Yao⁴,
GENG Haoxiang⁵,
LIU Yaqian⁶,
SUN Yong¹,
DENG Shu¹,
WANG Fei⁷,
YE Qin⁷,
FAN Yinguang⁵,
HUANG Yue'e⁸,
YE Jun⁹,
CHEN Yeji¹⁰,
LENG Ying¹⁰,
CHEN Jian²,
SUN Liang¹¹,
TANG Haiyan¹²,
TAN Xiaowei¹³,
MA Wanwan¹,
ZHU Biao¹,
AN Zhou⁷,
WANG Peng¹⁴,
DENG Guoqiang¹⁵,
BAO Min¹⁶,
LYU Yong⁴,
SU Hong⁵,
LI Jie¹⁷,
WANG Jinsheng¹⁸,
ZHANG Zhihua⁵,
ZHAO Yufeng¹⁹,
XU Yanlong¹,
WU Jiabing^{1
,
,}

1.
Anhui Center for Disease Control and Prevention, Hefei 230022, China
2.
Ma'anshan Center for Disease Control and Prevention, Ma'anshan 243000, China
3.
Hefei Center for Disease Control and Prevention, Hefei 230061, China
4.
Lu'an Center for Disease Control and Prevention, Lu'an 237000, China
5.
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230032, China
6.
School of Public Health, Bengbu Medical University, Bengbu 233030, China
7.
Wuhu Center for Disease Control and Prevention, Wuhu 241000, China
8.
School of Public Health, Wan Nan Medical College, Wuhu, 241002 China
9.
Department of Infectious Diseases, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
10.
Anhui Provincial Preventive Medicine Association, Hefei 230601, China
11.
Fuyang Center for Disease Control and Prevention, Fuyang 236000, China
12.
Dangtu Center for Disease Control and Prevention, Dangtu 243100, China
13.
Feidong Center for Disease Control and Prevention, Feidong 231611, China
14.
Suzhou Center for Disease Control and Prevention, Suzhou 234000, China
15.
Huangshan Center for Disease Control and Prevention, Huangshan 245000, China
16.
Chizhou Center for Disease Control and Prevention, Chizhou 247000, China
17.
Huainan Center for Disease Control and Prevention, Huainan 232001, China
18.
Anqing Center for Disease Control and Prevention, Anqing 246000, China
19.
Bozhou Center for Disease Control and Prevention, Bozhou 236814, China

Funds:

National Disease Control and Prevention Administration Public Health Talent Development Support Program 202303

More Information

Corresponding author: WU Jiabing, E-mail: wjb0386@126.com
Received Date: 2024-11-15
Rev Recd Date: 2025-04-14

Available Online: 2025-08-11

Publish Date: 2025-07-10

Abstract

Abstract

Mycoplasma pneumoniae (MP) infection is one of the predominant pathogens causing community-acquired pneumonia, which can lead to outbreaks in densely populated settings. Although MP outbreaks occur sporadically, there are currently no established guidelines, protocols, or standardized procedures for outbreak investigation and response. To address this gap, the Public Health Emergency Response Committee of the Anhui Preventive Medicine Association convened a panel of experts to develop a consensus document on the management of MP outbreaks. This consensus outlines criteria for defining outbreaks of MP, among other key aspects. It aims to provide a scientific reference to enhance MP outbreak response capabilities and to standardize on-site outbreak management practices in China.
- Mycoplasma pneumoniae,
- Outbreak response,
- Disease control,
- Expert consensus

FullText(HTML)

References(30)

References

[1]	Chen JD, Zhang J, Lu ZW, et al. Mycoplasma pneumoniae among Chinese outpatient children with mild respiratory tract infections during the coronavirus disease 2019 pandemic[J]. Microbiol Spectr, 2022, 10(1): e0155021. DOI: 10.1128/spectrum.01550-21.
[2]	张海情, 陈艳萍, 张瑾. 肺炎支原体疫苗研究进展[J]. 临床儿科杂志, 2022, 40(8): 634-640. DOI: 10.12372/jcp.2022.21e1322. Zhang HQ, Chen YP, Zhang J. Research progress of Mycoplasma pneumoniae vaccine[J]. J Clin Pediatr, 2022, 40(8): 634-640. DOI: 10.12372/jcp.2022.21e1322.
[3]	中华中医药学会儿童肺炎协作创新共同体, 中国中药协会儿童健康与药物研究专业委员会, 《中国实用儿科杂志》编辑委员会. 儿童肺炎支原体肺炎中西医结合诊治专家共识(2023年)[J]. 中国实用儿科杂志, 2024, 39(3): 161-167. DOI: 10.19538/j.ek2024030601. Children's Pneumonia Collaborative Innovation Community, Chinese Society of Traditional Chinese Medicine, Children's Health and Drug Research Professional Committee, China Association of Traditional Chinese Medicine, Editorial Board of Chinese Journal of Practical Pediatrics. Expert consensus on integrated traditional Chinese and western medicine in the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children(2023)[J]. Chinese Journal of Practical Pediatrics, 2024, 39(3): 161-167. DOI: 10.19538/j.ek2024030601.
[4]	Yan C, Xue GH, Zhao HQ, et al. Current status of Mycoplasma pneumoniae infection in China[J]. World J Pediatr, 2024, 20(1): 1-4. DOI: 10.1007/s12519-023-00783-x.
[5]	Esposito S, Argentiero A, Gramegna A, et al. Mycoplasma pneumoniae: a pathogen with unsolved therapeutic problems[J]. Expert Opin Pharmacother, 2021, 22(9): 1193-1202. DOI: 10.1080/14656566.2021.1882420.
[6]	Ding GD, Zhang XB, Vinturache A, et al. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia[J]. Eur J Pediatr, 2024, 183(7): 3001-3011. DOI: 10.1007/s00431-024-05519-1.
[7]	Deng ZL, Hu HY, Tang D, et al. Ultrasensitive, specific, and rapid detection of Mycoplasma pneumoniae using the ERA/CRISPR-Cas12a dual system[J]. Front Microbiol, 2022, 13: 811768. DOI: 10.3389/fmicb.2022.811768.
[8]	Wu QY, Pan XZ, Han DD, et al. New insights into the epidemiological characteristics of Mycoplasma pneumoniae infection before and after the COVID-19 pandemic[J]. Microorganisms, 2024, 12(10): 2019. DOI: 10.3390/microorganisms12102019.
[9]	Liu NN, Guo BH, Wang L, et al. The efficacy of ophiopogonanone B in treating the cough in mice infected with Mycoplasma pneumoniae[J]. Front Pharmacol, 2025, 16: 1397543. DOI: 10.3389/fphar.2025.1397543.
[10]	Lv YT, Sun XJ, Chen Y, et al. Epidemic characteristics of Mycoplasma pneumoniae infection: a retrospective analysis of a single center in Suzhou from 2014 to 2020[J]. Ann Transl Med, 2022, 10(20): 1123. DOI: 10.21037/atm-22-4304.
[11]	王冰洁, 张泓. 大环内酯类耐药肺炎支原体研究进展[J]. 检验医学, 2020, 35(10): 1070-1074. DOI: 10.3969/j.issn.1673-8640.2020.10.024. Wang BJ, Zhang H. Research progress of macrolide-resistant Mycoplasma pneumoniae[J]. Lab Med, 2020, 35(10): 1070-1074. DOI: 10.3969/j.issn.1673-8640.2020.10.024.
[12]	郭玉清, 林帆, 李柏松, 等. 医疗机构急性呼吸道传染病症状监测预警研究进展[J]. 安徽预防医学杂志, 2023, 29(6): 441-449. DOI: 10.19837/j.cnki.ahyf.2023.06.001. Guo YQ, Lin F, Li BS, et al. Febrile respiratory syndromic surveillance and early warning systems based on medical institutions[J]. Anhui J Prev Med, 2023, 29(6): 441-449. DOI: 10.19837/j.cnki.ahyf.2023.06.001.
[13]	Jiang ZL, Li SH, Zhu CM, et al. Mycoplasma pneumoniae infections: pathogenesis and vaccine development[J]. Pathogens, 2021, 10(2): 119. DOI: 10.3390/pathogens10020119.
[14]	Feldman N, Goldman SE. Atypical neurological manifestations of Mycoplasma pneumoniae: isolated abducens nerve palsy and masseter spasms in a healthy 22-year-old[J]. R I Med J (2013), 2025, 108(5): 37-39.
[15]	刘艳艳, 景淑军, 崔振泽. 重症肺炎支原体肺炎的临床研究进展[J]. 中国实用乡村医生杂志, 2022, 29(2): 31-33. Liu YY, Jing SJ, Cui ZZ. Clinical research progress of severe pneumonia Mycoplasma pneumonia[J]. Chinese Practical Journal of Rural Doctor, 2022, 29(2): 31-33.
[16]	Tanasescu AM. Cell culture techniques and practices to avoid contamination by fungi and bacteria in the research cell culture laboratory[J]. J Vis Exp, 2023: (197). DOI: 10.3791/64769.
[17]	郭石红. 猪支原体肺炎的科学防治[J]. 畜禽业, 2023, 34(11): 80-82. DOI: 10.19567/j.cnki.1008-0414.2023.11.024. Guo SH. Scientific prevention and treatment of Mycoplasma hyopneumoniae[J]. Livest Poult Ind, 2023, 34(11): 80-82. DOI: 10.19567/j.cnki.1008-0414.2023.11.024.
[18]	Wang X, Li MZ, Luo M, et al. Mycoplasma pneumoniae triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020[J]. Emerg Microbes Infect, 2022, 11(1): 1508-1517. DOI: 10.1080/22221751.2022.2078228.
[19]	Wang GT, Wu P, Tang R, et al. Global prevalence of resistance to macrolides in Mycoplasma pneumoniae: a systematic review and Meta-analysis[J]. J Antimicrob Chemother, 2022, 77(9): 2353-2363. DOI: 10.1093/jac/dkac170.
[20]	Rowlands RS, Meyer Sauteur PM, Beeton ML, et al. Mycoplasma pneumoniae: not a typical respiratory pathogen[J]. J Med Microbiol, 2024, 73(10): 001910. DOI: 10.1099/jmm.0.001910.
[21]	Meyer Sauteur PM, Beeton ML, European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycoplasma and Chlamydia Infections Study Group. Pneumonia outbreaks due to re-emergence of Mycoplasma pneumoniae[J]. Lancet Microbe, 2024, 5(6): e514. DOI: 10.1016/S2666-5247(23)00406-8.
[22]	Tang LY, Zheng KW, Ma LL, et al. Epidemiologic trends and changes in humoral immunity and lymphocyte subsets levels among hospitalized children with Mycoplasma pneumoniae infection during 2019-2023[J]. Eur J Clin Microbiol Infect Dis, 2024, 43(9): 1837-1845. DOI: 10.1007/s10096-024-04901-z.
[23]	Wang YS, Zhou YL, Bai GN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J]. World J Pediatr, 2024, 20(9): 901-914. DOI: 10.1007/s12519-024-00831-0.
[24]	Kong WN, Wang QQ, Zhuo JH, et al. The prevalence of Mycoplasma pneumoniae in children in Shandong, China before, during, and after COVID-19[J]. Front Pediatr, 2024, 12: 1479311. DOI: 10.3389/fped.2024.1479311.
[25]	Layton GR, Veater JB, Thombre R, et al. Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis[J]. Lancet Infect Dis, 2025, 25(4): e253-e254. DOI: 10.1016/S1473-3099(25)00059-3.
[26]	代春英, 程丽, 朱天吉, 等. 肺炎支原体感染临床特征及TGF-β1/Smads通路变化[J]. 中华医院感染学杂志, 2023, 33(22): 3423-3427. DOI: 10.11816/cn.ni.2023-230406. Dai CY, Cheng L, Zhu TJ, et al. Clinical features of mycoplasma pneumoniae infection and changes in the TGF-β1/Smads pathway[J]. Chin J Nosocomiol, 2023, 33(22): 3423-3427. DOI: 10.11816/cn.ni.2023-230406.
[27]	张新星, 顾文婧, 郝创利, 等. 2015-2020年苏州地区呼吸道感染住院患儿肺炎支原体流行病学特征[J]. 儿科药学杂志, 2022, 28(9): 29-33. DOI: 10.13407/j.cnki.jpp.1672-108X.2022.09.008. Zhang XX, Gu WJ, Hao CL, et al. Epidemiological characteristics of mycoplasma pneumon-iae in hospitalized children with respiratory tract infection in Suzhou area from 2015 to 2020[J]. Journal of Pediatric Pharmacy, 2022, 28(9): 29-33. DOI: 10.13407/j.cnki.jpp.1672-108X.2022.09.008.
[28]	Hu J, Ye YY, Chen XX, et al. Insight into the pathogenic mechanism of Mycoplasma pneumoniae[J]. Curr Microbiol, 2022, 80(1): 14. DOI: 10.1007/s00284-022-03103-0.
[29]	Kang DY, Yun KW, Lee T, et al. Treatment modalities for fever duration in children with Mycoplasma pneumoniae pneumonia[J]. Sci Rep, 2025, 15(1): 14860. DOI: 10.1038/s41598-025-99537-0.
[30]	陈旭. 微生物培养与快速血清学检验诊断儿童肺炎支原体感染的效果研究[J]. 新疆医学, 2022, 52(9): 1051-1053, 1081. Chen X. Study on the effectiveness of microbial culture and rapid serological testing in the diagnosis of Mycoplasma pneumoniae infection in children[J]. Xinjiang Medical Journal, 2022, 52(9): 1051-1053, 1081.